Drugs / MWX203
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07799025 | Jul 2025 → Mar 2026 overdue | — | Shanghai Minwei Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07803822 | Sep 2026 → Feb 2028 expected | hyperlipidemia, combined, 2 | Shanghai Minwei Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MWX203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07799025 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC)” NCT07799025 ↗ |